Epigenetic profiling of circulating cell-free DNA for early detection and minimal residual disease assessment in lung cancer: a focus on DNA methylation.
New blood-based cancer detection methods reading DNA patterns show far greater promise than mutation testing for identifying early-stage lung cancer.
This review synthesizes evidence on cfDNA epigenetic profiling approaches—methylation, fragmentomics, and nucleosome positioning—for early lung cancer detection and minimal residual disease assessment. The emerging multi-modal cfDNA epigenetic landscape offers substantially improved sensitivity over mutation-based ctDNA for the world's leading cancer killer.
What the study was
- Study design
- Systematic review
- Population
- High-risk individuals and lung cancer patients
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Frontiers in oncology
Why it surfaced
Comprehensive synthesis of cfDNA epigenomics for lung cancer early detection; establishes the methodological case for multi-modal liquid biopsy in highest-mortality cancer.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.